RCEL

AVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69

The average one-year price target for AVITA Medical (NasdaqCM:RCEL) has been revised to 26.69 / share. This is an increase of 6.80% from the prior estimate of 24.99 dated January 16, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 21.21 to a high of 42.00 / share. The average price target represents an increase of 56.08% from the latest reported closing price of 17.10 / share.

What is the Fund Sentiment?

There are 207 funds or institutions reporting positions in AVITA Medical. This is an increase of 4 owner(s) or 1.97% in the last quarter. Average portfolio weight of all funds dedicated to RCEL is 0.03%, a decrease of 36.95%. Total shares owned by institutions decreased in the last three months by 14.58% to 7,828K shares. RCEL / AVITA Medical, Inc. Put/Call Ratios The put/call ratio of RCEL is 0.53, indicating a bullish outlook.

What are Other Shareholders Doing?

RCEL / AVITA Medical, Inc. Shares Held by Institutions

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 816K shares representing 3.17% ownership of the company. No change in the last quarter.

IWM - iShares Russell 2000 ETF holds 592K shares representing 2.30% ownership of the company. In it's prior filing, the firm reported owning 573K shares, representing an increase of 3.14%. The firm decreased its portfolio allocation in RCEL by 7.23% over the last quarter.

Geode Capital Management holds 529K shares representing 2.06% ownership of the company. In it's prior filing, the firm reported owning 499K shares, representing an increase of 5.68%. The firm decreased its portfolio allocation in RCEL by 12.55% over the last quarter.

AWM Investment holds 497K shares representing 1.93% ownership of the company.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 362K shares representing 1.41% ownership of the company. In it's prior filing, the firm reported owning 355K shares, representing an increase of 2.13%. The firm decreased its portfolio allocation in RCEL by 8.93% over the last quarter.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.